The University of Southampton
University of Southampton Institutional Repository

Cost-effectiveness of tacrolimus ointment in adults and children with moderate and severe atopic dermatitis: twice-weekly maintenance treatment vs. standard twice-daily reactive treatment of exacerbations from a third party payer (U.K. National Health Service) perspective

Cost-effectiveness of tacrolimus ointment in adults and children with moderate and severe atopic dermatitis: twice-weekly maintenance treatment vs. standard twice-daily reactive treatment of exacerbations from a third party payer (U.K. National Health Service) perspective
Cost-effectiveness of tacrolimus ointment in adults and children with moderate and severe atopic dermatitis: twice-weekly maintenance treatment vs. standard twice-daily reactive treatment of exacerbations from a third party payer (U.K. National Health Service) perspective
Background: a twice-weekly maintenance treatment regimen with tacrolimus ointment for atopic dermatitis (AD) significantly delayed and reduced the number of disease exacerbations over a 12-month period compared with the standard reactive treatment regimen.

Objectives: to determine the cost-effectiveness of tacrolimus ointment used in the maintenance treatment regimen vs. the standard reactive treatment regimen for the management of moderate and severe AD in adults and children.

Methods: data from two pivotal phase III studies conducted in adults and children receiving 0·1% and 0·03% tacrolimus ointment, respectively, were used to populate a decision-analytic model. The costs and benefits associated with maintenance vs. reactive use of tacrolimus ointment were calculated over a 12-month period based on the clinical and quality of life data from the clinical trials. The analysis was conducted from the perspective of the U.K. National Health Service. Sensitivity analyses were conducted to assess the degree of uncertainty surrounding the results.

Results: for both adults and children with moderate and severe AD, twice-weekly maintenance treatment with tacrolimus ointment was shown to be a more effective and less costly (dominant) treatment regimen than the standard treatment regimen. Sensitivity analyses demonstrated that the model was robust and largely insensitive to changes in model parameters.

Conclusions: maintenance treatment with tacrolimus ointment for the management of moderate and severe AD provides incremental health benefits at a lower cost compared with the reactive treatment regimen
0007-0963
387-395
Healy, E.
400fc04d-f81a-474a-ae25-7ff894be0ebd
Bentley, A.
fa486be8-6cf9-4940-a357-6baeacfececb
Fidler, C.
5e321bd7-1470-4db1-adf6-1f787a657d11
Chambers, C.
bee0e2c3-8779-4a4b-8e69-ae18216a0df6
Healy, E.
400fc04d-f81a-474a-ae25-7ff894be0ebd
Bentley, A.
fa486be8-6cf9-4940-a357-6baeacfececb
Fidler, C.
5e321bd7-1470-4db1-adf6-1f787a657d11
Chambers, C.
bee0e2c3-8779-4a4b-8e69-ae18216a0df6

Healy, E., Bentley, A., Fidler, C. and Chambers, C. (2011) Cost-effectiveness of tacrolimus ointment in adults and children with moderate and severe atopic dermatitis: twice-weekly maintenance treatment vs. standard twice-daily reactive treatment of exacerbations from a third party payer (U.K. National Health Service) perspective. British Journal of Dermatology, 164 (2), 387-395. (doi:10.1111/j.1365-2133.2010.10141.x).

Record type: Article

Abstract

Background: a twice-weekly maintenance treatment regimen with tacrolimus ointment for atopic dermatitis (AD) significantly delayed and reduced the number of disease exacerbations over a 12-month period compared with the standard reactive treatment regimen.

Objectives: to determine the cost-effectiveness of tacrolimus ointment used in the maintenance treatment regimen vs. the standard reactive treatment regimen for the management of moderate and severe AD in adults and children.

Methods: data from two pivotal phase III studies conducted in adults and children receiving 0·1% and 0·03% tacrolimus ointment, respectively, were used to populate a decision-analytic model. The costs and benefits associated with maintenance vs. reactive use of tacrolimus ointment were calculated over a 12-month period based on the clinical and quality of life data from the clinical trials. The analysis was conducted from the perspective of the U.K. National Health Service. Sensitivity analyses were conducted to assess the degree of uncertainty surrounding the results.

Results: for both adults and children with moderate and severe AD, twice-weekly maintenance treatment with tacrolimus ointment was shown to be a more effective and less costly (dominant) treatment regimen than the standard treatment regimen. Sensitivity analyses demonstrated that the model was robust and largely insensitive to changes in model parameters.

Conclusions: maintenance treatment with tacrolimus ointment for the management of moderate and severe AD provides incremental health benefits at a lower cost compared with the reactive treatment regimen

This record has no associated files available for download.

More information

Published date: February 2011

Identifiers

Local EPrints ID: 185583
URI: http://eprints.soton.ac.uk/id/eprint/185583
ISSN: 0007-0963
PURE UUID: 25cf30a2-9d69-4b90-a6e3-a419677c2e2a

Catalogue record

Date deposited: 10 May 2011 14:31
Last modified: 14 Mar 2024 03:14

Export record

Altmetrics

Contributors

Author: E. Healy
Author: A. Bentley
Author: C. Fidler
Author: C. Chambers

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×